Olema Pharmaceuticals (OLMA) Non Operating Income (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Non Operating Income of $4.9 million for Q1 2026, up 9.21% year-over-year from $4.5 million in Q1 2025, and up 21.73% quarter-over-quarter from $4.0 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Non Operating Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Non Operating Income for 7 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 9.21% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $16.7 million (up 19.86% YoY), while the FY2025 annual figure was $16.2 million, up 27.09% from the prior year.
- Non Operating Income improved to $4.9 million in Q1 2026 per OLMA's latest filing, from $4.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $4.9 million in Q1 2026 and bottomed at $224000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $2.6 million across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 924.49% — and 2024, when it slipped 12.16%.
- Olema Pharmaceuticals' Non Operating Income stood at $1.0 million in 2022, then surged by 250.38% to $3.6 million in 2023, then retreated by 12.16% to $3.2 million in 2024, then increased by 25.68% to $4.0 million in 2025, then rose by 21.73% to $4.9 million in 2026.
- Business Quant data shows OLMA's Non Operating Income at $4.9 million in Q1 2026, $4.0 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 3.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.98 Mn |
| Mar 31, 2026 | 4.90 Mn |
| Dec 31, 2025 | 4.02 Mn |
| Sep 30, 2025 | 3.66 Mn |
| Jun 30, 2025 | 4.08 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | 3.37 Mn |
| Dec 31, 2023 | 3.64 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.32 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 502,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Mar 31, 2022 | 224,000.00 |
| Dec 31, 2021 | 119,000.00 |
| Sep 30, 2021 | 49,000.00 |